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Clinical Follow-up of Conjunctival Malignant Melanoma
Jungbum Choi, MD1, Min Kim, MD1, Hae Song Park2, Sang Yeul Lee, MD1
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Purpose: To investigate the clinical features and course of conjunctival malignant melanoma in Korea.
Methods: The medical records of 15 patients, 5 males and 10 females, diagnosed with conjunctival 
malignant melanoma who had been treated at Severance Hospital from May 1991 to March 2004 were 
reviewed retrospectively. The clinical parameters of the patients, tumors, and treatment were analyzed for 
their relation to outcome measures. 
Results: The mean age at the time of diagnosis was 53.4 years (±11.7 years). In all cases, the disease 
was unilateral and all patients had experienced at least one recurrence. Local lymph node metastasis was 
found in 3 patients (20%) and the mean time to metastasis was 3.5 years. Systemic metastasis was found 
in 6 patients (40%) and the mean time to metastasis was 9.3 years. There were 5 cases of tumor-related 
death (33.3%), 4 of which were attributed to systemic metastasis. The Kaplan-Meier estimates of cumulative 
survival rate were 90% at 30 months and 56.6% at 70 months. 
Conclusions: Although conjunctival malignant melanoma is a rare disease, it is life-threatening and complete 
tumor excision at an early stage is mandatory, as is additional therapy to prevent local recurrence and 
systemic metastasis.  Korean Journal of Ophthalmology 19(2):91-95, 2005
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Conjunctival malignant melanoma is extremely rare, but 
when developed can be fatal. The incidence of conjunctival 
malignant melanoma is 1.6% of all noncutaneous 
melanomas.1 In 1987, the Swedish National Cancer Registry 
reported 1,243 cases of new cutaneous malignant melanoma 
and 70 cases of uveal melanoma, but only 2 cases of new 
conjunctival malignant melanoma.2 In Korea, several cases 
have been reported, but without any details of progression 
and treatment.3 Hence, we report here the clinical outcome 
of conjunctival malignant melanoma cases experienced at our 
hospital. 
Materials and Methods
The medical records of 15 patients who were diagnosed 
with conjunctival malignant melanoma after biopsy from May 
1991 to March 2004 at our hospital were reviewed retrospec-
tively. The age at the time of diagnosis, gender, right eye/left 
eye, symptoms at the initial period, initial treatments prior to 
the transfer to our hospital, visual acuity, location of lesion, 
treatment methods, local recurrence, distant metastasis, 
whether or not exenteration was performed, and death 
pertinent to tumor were examined. The correlation of local 
recurrence and distant metastasis to death related to tumor 
was also examined. 
Results
The average age of the patients at the time of diagnosis 
was 53.4 years (±11.7 years), and all patients were 
transferred from other hospitals. There were 5 males (33.3%), 
10 females (66.7%), 6 right eyes, and 9 left eyes. As for 
initial symptoms, 9 patients were admitted primarily for lump 
(60%), which was the most prevalent symptom, and 1 patient 
visited a hospital for an expanding nevus. In regard to tumor 
location, there were 3 cases each of bulbar conjunctiva and 
palpebral conjunctiva (20%), 1 of conjunctival fornix, and 
8 of simultaneous invasion of the bulbar conjunctiva, 
palpebral conjunctiva, and caruncle, etc. (53.3%), which was 
the most prevalent presentation. Regarding the treatments 
performed at other hospitals, 12 cases were treated by 
excisional biopsy as the first treatment (80%), which was the 
most prevalent, followed by 1 case of resection and 
cryotherapy, and 1 case of incisional biopsy. The treatments 
performed at our hospital after the transfer were resection in 
5 cases (33.3%), wide resection and subsequent lid recon-
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Involved lymph node Treatment Survival time from diagnosis (months)
Case 1
Case 2
Case 3
Preauricular Cervical 
Infraauricular Parotid gland
Preauricular Submandibular
Radiation 
Total parotidectomy & RND
Parotidectomy & RND
134
70
141
RND: Radical neck dissection
Table 3. Clinical course of 3 patients with regional lymph node metastasis
Intrinsically numerical scalar variables
Variable Mean SD Minimum Maximum
Age at diagnosis (yr)
Duration of follow-up (mo)
Number of prior recurrences before referral
52.8
32.1
1.58
±11.67
±38.76
±1.24
34
1
0
69
141
5
SD: standard deviation.
Table 2. Summary of descriptive statistics on evaluated baseline study variables in 15 patients with conjunctival 
melanoma
Intrinsically categorical variables
Variables
Sex
Male
Female
 5 (33.3%)
10 (66.7%)
Involved eye
Right
Left
 6 (40%)
 9 (60%)
Origin
Unknown
De novo
PAM
Previous nevus
10 (66.7%)
 1 (6.7%)
 1 (6.7%)
 3 (20%)
Tumor location
Bulbar
Palpebral
Fornix (inferior)
Combined*
 3 (20%)
 3 (20%)
 1 (6.7%)
 8 (53.3%)
1st surgical technique before referral
Incisional biopsy
Excision 
Excision with cryotherapy
No treatment
 1 (6.7%)
12 (80%)
 1 (6.7%)
 1 (6.7%)
First treatment after referral
Excision
Excision with lid reconst. (Mod.Hughes)
Excision with RTx
Excision with Cryo/RTx
RTx followed by Excision
Inoperable case (RTx)
 5 (33.3%)
 2 (13.3%)
 1 (6.7%)
 3 (20%)
 1 (6.7%)
 3 (20%)
*Combined: Bulbar and palpebral/bulbar, palpebral and caruncular 
involvement.
Cryo: Cryotherapy, RTx: Radiation therapy.
Table 1. Summary of descriptive statistics on evaluated 
baseline study variables in 15 patients with conjunctival 
melanoma
struction by the modified Hughes method in 2 cases, local 
radiation after resection in 1 case, local radiation after 
resection and cryotherapy in 2 cases, and conventional 
radiation therapy in 2 inoperable cases. Additionally, there 
was 1 case transferred without treatment, after biopsy, 
cryotherapy and radiation therapy perfomed. The case of 
infeasible complete resection had local recurrence over a 
wide area. In the case with tumors invading the orbit, orbital 
exenteration was considered. However, as the patient refused 
such treatment, only local radiation therapy was performed 
(Tables 1, 2). There were 11 cases of local recurrence prior 
to transfer (73.3%) and the average number of recurrences 
was 1.58 times. There were 7 cases of local recurrence after 
transfer (46.6%) and the average number of recurrences was 
one. In all 15 cases, local recurrence was more prevalent than 
once. There were 3 cases of local lymph node metastasis 
(20%), and the mean interval from diagnosis to the 
development of metastasis was 3 years and 5 months. Radical 
lymph node dissection was performed in 2 of these cases, and 
radiation therapy in one (Table 3). There were 6 cases of 
systemic metastasis (40%), and the average interval to 
metastasis was 9 years and 3 months. Regarding distant 
metastasis sites, there were 2 cases of metastasis to the nasal 
cavity through the nasolacrimal duct (Table 4). In the 6 cases 
with systemic metastasis, 4 patients died. In the case of local 
recurrence and metastasis in the nasal cavity of the same side, 
local resection was performed and the patient remained under 
follow up. In another case, metastasis in the lung was 
Location
case 1
case 2
case 3
case 4,5
case 6
liver, bone
brain, lung, spine
lung
nasal cavity
rib
Table 4. Locations of systemic metastasis
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Fig. 1. Kaplan-Meier estimates of survival in 15 consecutive 
patients with conjunctival malignant melanoma.
confirmed by positron emission tomography (PET) test and 
the patient remained under follow up. There were 5 deaths 
related to tumor (33.3%), and 4 cases of systemic metastasis. 
The survival rate related to tumors as predicted by 
Kaplan-Meier estimate was 90% survival after 30 months, 
and 56.6% survival after 70 months (Fig. 1). During the 
course, exenteration was performed in 2 cases, one of which 
developed systemic metastasis and the other patient stopped 
the treatment voluntarily after local recurrence and 
subsequently died. Due to the small sample size, it was not 
possible to examine the statistical significance of the 
prognostic factors for recurrence and metastasis such as 
clinical patterns (patient age, gender, tumor origin, location, 
limbus invasion, tumor size and thickness), initial treatment 
methods, presence of local recurrence, etc. 
Discussion
Conjunctival malignant melanoma is extremely rare, but 
may be fatal. Most malignant melanomas are developed in 
sun-exposed skin, although it also develops rarely in other 
tissues. Conjunctival malignant melanoma is developed de 
novo, from an existing nevus or a primary acquired 
melanosis. The reported incidence has varied widely. The 
development from primary acquired melanosis has been 
reported as 9% by Werschnik and Lommatzsch,6 57.4% by 
Paridaens et al,7 53% by Shields CL et al,8 and 42.1% by 
Anastassiou et al.9 The range of reported incidence for the 
development from existing nevi is 4~39.1%.4-9 The reported 
incidence for the absence of precancerous lesions ranges from 
15.9~47%.4-9 In our study, the incidence was higher in 
females (10 cases) than males (5 cases). Conjunctival 
malignant melanoma occurs primarily in the bulbar 
conjunctiva. Shields et al8 have reported that among 150 
cases of conjunctival malignant melanoma patients, 92% (138 
cases) had the lesion on the bulbar conjunctiva, 3% in the 
conjunctival fornix, 4% in the palpebral conjunctiva, and 
0.67% (1 case) each in the plica semilunaris and the caruncle. 
Werschnik and Lommatzsch6 classified the lesion sites as 
favorable locations (bulbar conjunctiva and limbus) and 
unfavorable locations (caruncle, fornix, corneal 
parenchyma, and palpebral conjunctiva). In 85 patients, the 
lesion occurred in the favorable location for 56.5% and in the 
unfavorable location for 43.5%. In our study, the cases 
invading the bulbar conjunctiva, tarsal conjunctiva and 
caruncle were the most prevalent (8 cases, 53.3%). Although 
the prognosis according to location could not be assessed, the 
survival rate was high in the 3 cases with the lesion limited 
to the bulbar conjunctiva. However, among these 3 cases, in 
the 2 cases with local metastasis and systemic metastasis, it 
appeared that appropriate treatments were performed to 
increase the survival (Table 3). 
The recurrence rate reported in other studies has ranged 
from 20~50%.6,8,9 In our study, local recurrence was 100% 
(all 15 cases) because local recurrence was developed prior 
to the transfer in most patients (14 cases out of 15 cases). 
Histopathological factors pertinent to fatal metastasis have 
been reported to be tumor thickness and width, epithelioid 
cells, from presence of atypical melanin cells in case of 
development from primary acquired melanosis, pagetoid 
invasion, in situ growth pattern, development in the 
caruncle and palpebral conjunctiva, reduced small 
polygonal cells, and mild inflammation and abundant 
mitoses.4,10 
Surgical resection is the therapy of choice for conjunctival 
malignant melanoma. Shields et al11 have reported a 
complete resection technique by no-touch technique. 
No-touch technique involves minimal tumor manipulation 
and partial lamellar scleroconjunctivectomy, to remove the 
tumor without touching the affected areas. After tumor 
resection, cryotherapy on the surrounding bulbar conjunctiva 
is performed. Additional cryotherapy has been reported to 
prevent recurrence. DePotter et al12 have reported that the 
only clinical factor associated with distant metastasis is local 
recurrence, and that local recurrence, in turn, is related to 
surgical methods. In our study, among 15 cases, resection and 
cryotherapy were performed in parallel in 1 case (6.6%) prior 
to the transfer and in 2 cases (13.3%) after the transfer. 
Werschnik and Lommatzsch6 have reported two issues 
demanding attention in the local resection of conjunctival 
malignant melanoma. First, during tumor removal, even 
under the microscope, the tumor boundary is not clear. 
Shields et al11 have reported that tumors could be removed 
completely by drawing a picture showing the shape and 
boundary of the tumor with a slit lamp examination prior to 
surgery and then performing surgery based on the picture. 
Second, for surgery on the sclera and cornea, tumor cells may 
be leaked to the globe. To prevent this, they recommended 
the elimination of tumor cells by treating with alcohol or 
formalin prior to the surgery and alternatively, the 
administration of mitomycin eye drops immediately after 
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operation.11 For cases of difficult primary suture due to wide 
resection, coverage of the removed area using amniotic 
membrane was recommended.13 The advantages of using 
amniotic membrane are that, in addition to the rapid wound 
healing effect, recurrence could be detected readily as the 
amniotic membrane is transparent. Espana et al14 have 
reported that for resections larger than 20 mm, treatment with 
amniotic membrane ensured rapid wound healing and few 
complications. 
It has been reported that even the orbital exenteration of 
conjunctival malignant melanoma at its early stage did not 
increase the long-term survival rate.10 Hence, orbital 
exenteration should be considered only when the tumor has 
invaded the orbit or local recurrence has occurred over a 
wide area.8 In our study, none of the patients were initially 
treated by orbital exenteration, although in 2 patients, both 
of whom died, it was performed during the follow up period. 
Additional known adjuvant therapies are the previously 
described cryotherapy, radiation therapy, and local treatment 
with mitomycin eye drops.11,15,16 
Conjunctival malignant melanoma metastasizes in the 
preauricular lymph, parotid lymph, and submandibular lymph 
nodes, dependent on the location of the lesion in the 
conjunctiva. Esmaeli et al17 have reported the detection of 
microscopic metastasis of the sentinel lymph node and its 
appropriate treatment. Amato M et al18 were able to detect 
more than 1 sentinel lymph node metastasis by the test using 
Technetium Tc-99m sulfur colloid pre- and post-surgery. 
Park et al19 also confirmed the sentinel lymph node 
metastasis by performing lymphoscintigraphy after surgery in 
conjunctival malignant melanoma patients. Seppo and Tero20 
have reported that due to the longer survival period of 
patients with metastasis only in the lymph nodes at the early 
period than of patients with systemic metastasis, it was 
important to prevent systemic metastasis by treating the 
patients with lymph node metastasis. In the cases of 
metastasis in the sentinel lymph nodes, radical lymphade-
nectomy was performed, followed by adjuvant therapies. 
Adjuvant therapies are local radiation therapy in the vicinity 
of the lymph nodes, systemic administration of interferon, 
chemotherapy, and combination therapies. Although the 
studies on cutaneous malignant melanoma are ongoing, its 
effectiveness has not been elucidated yet.21-23 
Lommatzsch et al24 have reported a 10-year local 
recurrence rate of 24% and a 10-year fatality rate of 23% for 
metastasis. They also reported that local recurrence and 
metastasis rates increased with larger tumors. Shields et al8 
have reported that metastasis was developed in 14~27% of 
patients, and that 30 % of patients died of metastasis after 
10 years. In our study, systemic metastasis was developed in 
6 cases (40%), with a death rate related to tumors of 33.3%.
On regard to survival analysis, our results showed higher 
mortality rate than that of previous reports, which may be 
related to small number of patients and the severe conditions 
of the lesions when transferred to our hospital.
The shortcomings of our study were the small study 
population, and the insufficiently detailed information on 
tumor clinical patterns. Nevertheless, the study demonstrated 
that the treatment for conjunctival malignant melanoma has 
not been clearly established. Conjunctival malignant 
melanoma is extremely rare, but potentially fatal. Hence, it 
is believed that its survival rate may be improved by the 
prevention of recurrence and metastasis through complete 
resection, the early application of adjuvant therapies and the 
early detection of metastasis in the sentinel lymph node. 
Future research examining the effect of each clinical pattern 
on the prognosis with a large study population is required. 
References
1) Scott J, Fraumeni JF, Lee JA. Melanomas of the eye and 
other noncutaneous sites: epidemiologic aspects. J Natl 
Cancer Inst 1976;56:489-91.
2) Seregard S, Koch E. Conjunctival malignant melanoma in 
Sweden 1969-91. Acta Ophthalmol 1992;70:289-96.
3) Kong YT, Kwak YJ, Kim JC, Song DJ. A case of 
malignant melanoma of conjunctiva. J Korean Ophthalmol 
Soc 1984;25:235-7.
4) Folberg R, McLean IW, Zimmerman LE. Malignant 
melanoma of the conjunctiva. Hum Pathol 1985;16:136-43.
5) Norregaard JC, Gerner N, Jensen OA, Prause JU. Malignant 
melanoma of the conjunctiva: occurrence and survival 
following surgery and radiotherapy in a Danish population. 
Graefes Arch Clin Exp Ophthalmol 1996;234:569-72.
6) Werschnik C, Lommatzsch PK. Long-term follow-up of 
patients with conjunctival melanoma. Am J Clin Oncol 
(CCT) 2002;25:248-55.
7) Paridaens ADA, Minassian DC, McCartney ACE, 
Hungerford JL. Prognostic factors in primary malignant 
melanoma of the conjunctiva: a clinocopathological study of 
256 cases. Br J Ophthalmol 1994;78:252-9.
8) Shields CL, Shields JA, Gunduz K, et al. Conjunctival 
melanoma: risk factors for recurrence, exenteration, 
metastasis and death in 150 consecutive patients. Arch 
Ophthalmol 2000;118:1497-507.
9) Anastassiou G, Heiligenhaus A, Bechrakis N, et al. 
Prognostic value of clinical and histopathological 
parameters in conjunctival melanomas: a retrospective 
study. Br J Ophthalmol 2002;86:163-7.
10) Paridaens ADA, McCartney ACE, Minassian DC, Hungerford 
JL. Orbital exenteration in 95 cases of conjunctival 
malignant melanoma. Br J Ophthalmol 1994;78:520-8.
11) Shields JA, Shield CL, DePotter P. Surgical approach to 
conjunctival tumors: The 1994 Lynn B. McMahan Lecture. 
Arch Ophthalmol 1997;115:808-15.
12) DePotter P, Shields CL, Shields JA, et al. Clinical predictive 
factors for development of recurrence and metastasis in 
conjunctival melanoma: a review of 68 cases. Br J 
Ophthalmol 1993;77:624-30.
13) Paridaens D, Beekhius H, Bosh W, et al. Amniotic 
membrane transplantation in the management of conjunc-
tival melanoma and primary acquired melanosis with atypia. 
Br J Ophthalmol 2001;85:658-61.
14) Espana EM, Prabhasawat P, Grueterich M, et al. Amniotic 
membrane transplantation for reconstruction after large 
ocular surface neoplasm. Br J Ophthalmol 2002;86:640-5.
15) Lederman M, Wybar K, Busby E. Malignant epibulbar 
melanoma: natural history and treatment by radiotherapy. 
JB Choi, et al. CLINICAL FOLLOW-UP OF CONJUNCTIVAL MALIGNANT MELANOMA
95
Br J Ophthalmol 1984;68:605-17.
16) Finger PT, Milner MS, McCormick SA. Topical chemo-
therapy for conjunctival melanoma. Br J Ophthalmol 1993; 
77:751-3.
17) Esmaeli B. Advances in the management of malignant 
tumors of the eyelid and conjunctiva : the role of sentinel 
lymph node biopsy. Int Ophthalmol Clin 2002;42:151-62.
18) Amato M, Esmaeli B, Ahmadi MA, et al. Feasibility of 
preoperative lymphoscintigraphy for identification of 
sentinel lymph nodes in patients with conjunctival and 
periocular skin malignancies. Ophthal Plast Reconstr Surg 
2003;19:102-6.
19) Park CS, Son JH, Chung WS, Cho IH. Lymphoscintigraphy 
of eyeball and ocular adnexal malignant tumors. J Korean 
Ophthalmol Soc 2004;45:893-8.
20) Seppo T, Tero K. Metastatic pattern and survival in 
disseminated conjunctival melanoma. Ophthalmology 2004; 
111:816-21.
21) Kirkwood J, Strawderman M, Ernstoff M, et al. Interferon- 
alpha-2b adjuvant therapy of high-risk resected cutaneous 
melanoma: the Eastern Cooperative Oncology Group Trial 
EST 1684. J Clin Oncol 1996;14:7-17.
22) Buzaid AC, Colome M, Bedikian A, et al. Phase II study 
of neoadjuvant concurrent biochemotherapy in melanoma 
patients with local-regional metastases. Melanoma Res 
1998;8:549-56.
23) Eton O, East M, Legha SS, et al. Pilot study of 
intra-arterial cisplatin and intravenous vinblastine and 
dacarbazine in patients with melanoma in-transit metastases. 
Melanoma Res 1999;9:483-9.
24) Lommatzsch PK, Lommatzsch RE, Kirsch I, Furman P. 
Therapeutic outcome of patients suffering from malignant 
melanoma of the conjunctiva. Br J Ophthalmol 1990;74: 
615-9.
